Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
03 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
28 mars 2024 04h25 HE
|
Clinuvel Pharmaceuticals Limited
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
27 mars 2024 08h05 HE
|
Aeterna Zentaris Inc
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...
Nutra Pharma Corp. Reaches Settlement with SEC
22 mars 2024 16h39 HE
|
Nutra Pharma Corp.
Nutra Pharma Corp. Reaches Settlement with SEC
SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America
20 mars 2024 10h00 HE
|
SERB Pharmaceuticals
Paris, March 20, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an...
Feeding Tubes Market Size to Surpass Around US$ 9.69 Billion 2030, Recording a CAGR of 6.2% | Report by CoherentMI
20 mars 2024 06h21 HE
|
CMI
Burlingame, March 20, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Feeding Tubes Market was valued at US$ 6.34 Billion in the year 2023 and is anticipated to reach US$ 9.69...
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
19 mars 2024 14h20 HE
|
Spherix Global Insights
EXTON, PA, March 19, 2024 (GLOBE NEWSWIRE) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising...
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
18 mars 2024 14h37 HE
|
PRISM MarketView
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
14 mars 2024 17h18 HE
|
Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
14 mars 2024 15h11 HE
|
Spherix Global Insights
EXTON, PA, March 14, 2024 (GLOBE NEWSWIRE) -- The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of two new...